{
  "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5",
  "docSlug": "adb5c4514a6016378ffb63c7d4422971",
  "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides",
  "authorId": "tcr2-therapeutics",
  "authorName": "TCR2 Therapeutics",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 34,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 22,
  "notes": "The slide uses a central human anatomy diagram to map specific cancer types to their respective mesothelin expression rates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/12",
  "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5",
  "deckJsonHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5.json",
  "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.3,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Percentage of patients with mesothelin surface expression",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8d01421-2d03-4c68-9a94-6cfb1b4d97d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.4,
        "y": 0.25
      },
      "kind": "image",
      "text": "Human anatomy diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "702bb7cd-5a80-4545-bcbb-a0ef055e9ab4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.25,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "List of cancer indications with population counts and clinical data points",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7081fe4-8923-46be-ab8b-2333f91b200e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.35,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "NSCLC, Non-Small Cell Lung Cancer; ORR, Overall Response Rate. Refs: Inaguma 2017, SEER Statistics, Morello 2016, Tozbikian 2014",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf869016-415b-438f-a170-101b7c11b4b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "~215,000 Patients Across Multiple Target Indications",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be670148-982e-46d6-ac5e-373ccc781054",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Significant Potential Opportunity in Mesothelin-Expressing Solid Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "065b2f0f-4196-433c-a7e0-f500761c4bd9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-sizing",
      "slug": null,
      "matchId": "ee1ed24e-dd0d-4c5b-8092-056490630cdc",
      "evidence": "Quantifies total addressable patient population across segments",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 18,
      "from": 8,
      "beatId": "fd7bc9b8-ed02-40c1-b1d1-66cb54ef449d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 12,
      "from": 12,
      "beatId": "ec90fa2c-0c7b-4213-9966-0575ae439a11",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The document discusses the market potential for TRuC-T cell therapy.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 8,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "0a2012e0-6a06-4e15-803c-e8ae832be1d6",
      "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.",
      "position": 1,
      "objective": "How can TRuC-T cell therapy address the needs of patients with solid tumors?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}